Baricitinib/remdesivir should be used to treat suspected or laboratory-confirmed COVID-19 in hospitalized adults and pediatric patients ≥ age 2 years who require supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation.
An analysis of renal outcomes in the PARAGON-HF trial revealed sacubitril/valsartan slows progression of kidney disease in patients with heart failure with preserved ejection fraction compared to valsartan alone.
Bamlanivimab is a neutralizing recombinant IgG1 monoclonal antibody that connects to the receptor-binding domain of the spike protein of SARS-CoV-2. The drug blocks attachment and entry of the virus into human cells.
Cannabidiol (CBD) is one of two major constituents of marijuana and is the non-psychoactive component of cannabis. As its popularity has grown, questions about CBD from patients to their primary care clinicians have increased dramatically. As a patient advocate interpreting the available evidence, the primary care clinician needs to recognize how CBD differs from marijuana, what its clinical utility might be, and what its risks are.
Drug delivery platform will release medication for monthly dosing
August 30, 2019
Although lowering side effects plays an important role in oral contraceptive compliance, one of the biggest challenges for patients is adhering to the daily schedule of the pill. Forgetting one to three pills per cycle is a frequent problem among 15-51% of users, particularly among adolescents. Lyndra Therapeutics has received a $13 million grant from the Bill & Melinda Gates Foundation and is setting out to remove the daily pill compliance challenge. The company is in early development of a monthly oral contraceptive to provide women with a discreet, noninvasive, reversible contraception option.